aminostigmine: a reversible inhibitor of cholinesterase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 46786029 |
| MeSH ID | M0191089 |
| Synonym |
|---|
| aminostigmine |
| DTXSID30989995 |
| 2-[(dimethylamino)methyl]pyridin-3-yl dimethylcarbamate--hydrogen chloride (1/1) |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The half-life period of aminostigmine exceeded considerably that of earlier studied carbamates and correlated with the clinical manifestations of the drug effects." | ( [New data on the pharmacokinetics of aminostigmine]. Chepur, SV; Panov, PB; Prozorovskiĭ, VB; Vorob'ev-Desiatovskiĭ, NV, ) | 0.13 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||